Recursion Pharmaceuticals (RXRX) EBIAT (2020 - 2025)
Historic EBIAT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.
- Recursion Pharmaceuticals' EBIAT fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
- Latest data reveals that Recursion Pharmaceuticals reported EBIAT of -$162.3 million as of Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' EBIAT registered a high of -$30.7 million during Q1 2021, and its lowest value of -$202.5 million during Q1 2025.
- For the 5-year period, Recursion Pharmaceuticals' EBIAT averaged around -$92.3 million, with its median value being -$76.7 million (2023).
- In the last 5 years, Recursion Pharmaceuticals' EBIAT crashed by 15201.04% in 2021 and then soared by 1145.95% in 2022.
- Recursion Pharmaceuticals' EBIAT (Quarter) stood at -$64.9 million in 2021, then rose by 11.46% to -$57.5 million in 2022, then crashed by 61.75% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then grew by 9.31% to -$162.3 million in 2025.
- Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.